GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney.
These press releases are intended for business journalists and analysts/investors
Australian and New Zealand health innovators encouraged to apply for partnership with GSK to turn their ideas into reality.
Panadol is approved by the TGA for the effective relief of backache. The results of the PACE study are not expected to lead to changes in the current recommendations that paracetamol should remain a first line analgesic in low back pain.
GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. 1
GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD), also known as “chronic bronchitis,” “smoker’s cough” or “emphysema”.
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD) which is also known as “chronic bronchitis,” “smoker’s cough” or emphysema”.
Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner held in Launceston last week.
GSK’s 2014 Immunisation Grants for local communities were launched today at the Public Health Association of Australia’s 14th annual immunisation conference. The grants aim to help improve access, coverage and timely delivery of vaccination services.
GSK has previously provided detailed product information and clinical studies to CHOICE and would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.
GSK Australia reported to the Australian Securities and Investment Commission (ASIC) for 2013, sales of $1,414m and a total profit before tax of $42m.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.